DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms

Information source: University of British Columbia
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hot Flushes; Night Sweats

Intervention: Oral micronized progesterone (Drug); placebo (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: University of British Columbia

Official(s) and/or principal investigator(s):
Jerilynn C Prior, MD FRCPC, Principal Investigator, Affiliation: University of British Columbia

Overall contact:
Jerilynn C Prior, MD, FRCPC, Phone: (604) 875-5927, Email: jerilynn.prior@ubc.ca


The purpose of this study is to test whether a oral micronized progesterone reduces the score, number and severity of hot flushes and night sweats in perimenopausal women. Oral micronized progesterone is molecularly identical to human progesterone, a steroid hormone. It is sold by prescription for use to prevent endometrial cancer in women taking estrogen in menopause. This research study will test whether progesterone reduces perimenopausal hot flushes and night sweats. It will also test whether progesterone improves sleep disturbances and anxiety.

Clinical Details

Official title: Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Vasomotor Symptoms (VMS)/ VMS Score

Secondary outcome:

Frequency of VMS

Severity of VMS

Sleep problems and anxiety

Detailed description: This is a randomized, placebo-controlled trial of oral micronized progesterone (300 mg daily at bedtime) for perimenopausal women living anywhere in Canada. Using the self-reported maximum menstrual cycle length in the previous year, women will be stratified as in Early Perimenopause (<60 days) or Late Perimenopause (>=60 days). The design includes a 28-day baseline run-in followed by 12 weeks of randomized therapy.


Minimum age: 35 Years. Maximum age: 58 Years. Gender(s): Female.


Inclusion Criteria: 1. Between 35-58 years of age 2. At least 4 vasomotor symptoms (VMS) per day, on average, for at least 2/4 weeks or at least 56 over a four-week period. In addition, women should report having VMS of moderate or severe rather than mild intensity. Women reporting fewer VMS than this, but who report night sweats that awaken them from sleep on two or more nights per week will also be included. 3. Perimenopausal status either based on irregularity of menstrual periods, or by onset of new perimenopausal symptoms in women with regular periods. 4. At least one menstrual period within 12 months of study enrollment 5. Ability and willingness to complete the Daily Perimenopause Hot Flush Calendar recording instrument. 6. Ability to understand, speak, read and write English. 7. Women who are at high risk for breast cancer (ie first degree relative with breast cancer, known/suspected history of breast cancer) will be required to have a normal mammogram and clinical breast examination within 12 months of study enrollment. Exclusion Criteria: 1. VMS without perimenopausal etiology. 2. Women who have had a hysterectomy and/or ovariectomy. 3. Peanut allergy (because peanut oil is used in the progesterone formulation.) 4. Current or recent (within the last 6-mos.) use of hormonal therapies (estrogen, progesterone, hormonal contraceptives, hormonal fertility treatments), or plans to initiate use during the study period. Two exceptions: women using progestin-releasing intrauterine device (IUD) will not be excluded as it is felt that level of hormone released will not have an effect on VMS and women taking very low-dose transdermal progesterone therapies who have VMS and meet inclusion criteria will be considered on a case-by-case basis. If enrolled, they will be required to continue and document use of this very low-dose hormone therapy throughout the entire trial. 5. Planned pregnancy or fertility treatment during the study period. 6. Women who are breastfeeding. 7. Participants with a score greater or equal to 15 on the Personal Health Questionnaire (PHQ-9) will be assessed on a case-by-case basis. Women assessed as needing further investigation and/or treatment for depression will be excluded.

Locations and Contacts

Jerilynn C Prior, MD, FRCPC, Phone: (604) 875-5927, Email: jerilynn.prior@ubc.ca

Participation from home or in-person at University of British Columbia/Centre for Menstrual Cycle and Ovulation Research (CeMCOR)/Vancouver Coastal Health Research Institute, Vancouver, British Columbia V5Z 1M9, Canada; Recruiting
Jerilynn C Prior, MD FRCPC, Phone: (604) 875-5927, Email: jerilynn.prior@ubc.ca
Andrea Cameron, RN BScN, Phone: (604) 875-5960, Email: andrea.cameron@ubc.ca
Jerilynn C Prior, MD FRCPC, Principal Investigator
Christine L Hitchcock, PhD, Sub-Investigator
Shirin Kalyan, PhD, Sub-Investigator
Patricia Janssen, PhD, Sub-Investigator
Michelle Fung, MD MHSc FRCPC, Sub-Investigator
Joel Singer, PhD, Sub-Investigator
Sandra Sirrs, MD FRCPC, Sub-Investigator
Andrea Cameron, RN BScN, Sub-Investigator
Additional Information

Centre for Menstrual Cycle and Ovulation Research

Related publications:

Prior JC, Hitchcock, CL. Progesterone for Vasomotor Symptoms: A 12-week Randomized, Masked Placebo-controlled Trial in Healthy, Normal-Weight Women 1-10 Years Since Final Menstrual Flow (Abstract). Endocrine Reviews 31(3): S51, 2010.

Starting date: October 2011
Last updated: April 7, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017